Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of SAR445399, a drug administered by injection, in adults with moderate to severe hidradenitis suppurativa. This multinational, randomized, double-blind, placebo-controlled Phase 2 study aims to compare two different doses of SAR445399 with a placebo to find the best dose for treating this condition. Participants will be randomly assigned to receive one of two SAR445399 dose regimens or a matching placebo. The treatment period lasts 32 weeks, including a 16-week initial double-blind phase followed by a 16-week treatment-blinded extension period. The total study duration for each participant is up to 46 weeks, with a total of 16 study visits scheduled throughout this time. During the study, participants will be monitored through various assessments including clinical response measures such as Hidradenitis Suppurativa Clinical Response HiSCR levels, severity scoring, skin pain ratings, quality of life questionnaires, laboratory tests, vital signs, and electrocardiograms. Researchers will also track drug concentrations and immune responses. Safety will be closely monitored throughout the study and extension period to evaluate any adverse events or significant changes in health.
Actively Recruiting
Degenerative cervical myelopathy DCM is a common cause of spinal cord dysfunction in adults, leading to progressive problems with movement, sensation, and autonomic functions. Standardized and accurate assessment of neurological function is crucial for making clinical decisions, predicting outcomes, and comparing treatments. This study aims to create and validate a Turkish version of the Modified Japanese Orthopaedic Association mJOA score, a widely used tool that measures neurological status in DCM patients, since no validated Turkish version currently exists. The study is a prospective, cross-sectional validation involving adult patients with confirmed DCM. Researchers will culturally adapt the mJOA score into Turkish using a standardized translation process. They will review previous cervical MRI scans to assess the level of spinal cord damage and collect clinical data including age, sex, symptom duration, and treatment status. The Turkish mJOA scores will be compared with other clinical scales like the Neck Disability Index and Nurick grading system to evaluate validity. Reliability will be tested by comparing scores from two independent evaluators and by repeating the test after 7 to 14 days in stable patients. Participants will attend outpatient clinics where clinical scales and questionnaires will be administered. The study will record the time needed to complete the Turkish mJOA and note any difficulties. Researchers will analyze correlations between scores and evaluate consistency between raters and over time. The main outcomes include the Turkish mJOA score and Neck Disability Index on the first day. This research will help standardize DCM assessment in Turkish clinical practice and support international comparisons.